Related references
Note: Only part of the references are listed.IgG4-Related Disease A Clinical Case Series From a Tertiary Care Center in India
Lalit Duggal et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2022)
Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study
Emanuel Della-Torre et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)
Involvement of two or more sets of lacrimal glands and/or major salivary glands is related to greater systemic disease activity due to multi-organ involvement in IgG4-related dacryoadenitis/sialadenitis
Yoshinori Takahashi et al.
MODERN RHEUMATOLOGY (2021)
Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China
Zhen Zhao et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Major salivary gland enlargement in IgG4-related disease is associated with multiorgan involvement and higher basal disease activity
Eduardo Martin-Nares et al.
MODERN RHEUMATOLOGY (2020)
Long-term outcomes of ocular adnexal lesions in IgG4-related ophthalmic disease
Toshinobu Kubota et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2020)
Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis
Dina Omar et al.
RHEUMATOLOGY (2020)
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease
Zachary S. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Advances in the diagnosis and management of IgG4 related disease
Marco Lanzillotta et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Clinical manifestations, clinical course, and outcomes of immunoglobulin G4-related disease
Kamonchanok Phaopraphat et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial
Fei Yunyun et al.
RHEUMATOLOGY (2019)
Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts
Zachary S. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients
Liwen Wang et al.
RHEUMATOLOGY (2019)
The treatment outcomes in IgG4-related orbital disease: a systematic review of the literature
Sanne E. Detiger et al.
ACTA OPHTHALMOLOGICA (2019)
Clinicoserological factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease
Ji Wook Hong et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2018)
Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial
Qingjun Wu et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2017)
Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients
Kensuke Kubota et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients
Mikael Ebbo et al.
PLOS ONE (2017)
Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years
Motohisa Yamamoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Rituximab for IgG4-related disease: a prospective, open-label trial
Mollie N. Carruthers et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
IgG4-Related Disease: Dataset of 235 Consecutive Patients
Dai Inoue et al.
MEDICINE (2015)
IgG4-Related Disease Clinical and Laboratory Features in One Hundred Twenty-Five Patients
Zachary S. Wallace et al.
ARTHRITIS & RHEUMATOLOGY (2015)
International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease
A. Khosroshahi et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Share Paper
